Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474617 | 0.83 | P2RX7 (0.34) | P2RX7DGAT1 | |
| SCHEMBL21471732 | 0.83 | DGAT1 (0.33) | P2RX7DGAT1 | |
| SCHEMBL21478314 | 0.79 | — | — | |
| SCHEMBL21471676 | 0.78 | CHRM2 (0.32) | — | |
| SCHEMBL21471714 | 0.74 | CHRM2 (0.38) | — | |
| SCHEMBL20599068 | 0.74 | NOTUM (0.46) | — | |
| SCHEMBL21474620 | 0.73 | MAPK14 (0.41) | — | |
| SCHEMBL21471717 | 0.73 | MAPK14 (0.41) | — | |
| SCHEMBL21471614 | 0.73 | KDM4E (0.36) | — | |
| SCHEMBL21471675 | 0.73 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | P2RX7 872/4885DGAT1 3940/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | P2RX7 872/4885DGAT1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.